Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Cancer Lett
    February 2026
  1. XIE Z, Li S, Yang J, Zhang Z, et al
    SNHG18 deficiency reprograms arginine metabolism to foster an immunosuppressive microenvironment in prostate cancer bone metastasis.
    Cancer Lett. 2026;644:218326.
    >> Share

  2. SHIGETA K, Takamori S, Ozawa H, Haratake N, et al
    M1C Mediates LINE-1 Transcription in PARP Inhibitor-Treated Prostate Cancer Cells.
    Cancer Lett. 2026 Feb 12:218320. doi: 10.1016/j.canlet.2026.218320.
    >> Share

    January 2026
  3. MAK CSL, Zhu M, Fu J, Liang X, et al
    KDM4A promotes NEPC progression through regulation of MYC expression.
    Cancer Lett. 2026;638:218184.
    >> Share

  4. ZHANG Y, Zhao H, Xu P, Liu K, et al
    The Zeb1/system X(c)(-) axis safeguards iron-loaded cancer-associated fibroblasts against ferroptosis and promotes immunosuppression in prostate cancer.
    Cancer Lett. 2026;639:218243.
    >> Share

    December 2025
  5. GUAN Y, Cao F, Luo Y, Li J, et al
    High-fat diet induced ECM remodeling attenuates chemosensitivity in prostate cancer via activating Piezo1-dependent mitochondria-ER contacts.
    Cancer Lett. 2025 Dec 9:218204. doi: 10.1016/j.canlet.2025.218204.
    >> Share

    November 2025
  6. MATOS AC, Lima M, Miranda-Goncalves V, Indraccolo S, et al
    Overcoming Radioresistance in Prostate Cancer by Targeting DNA Damage Repair.
    Cancer Lett. 2025 Nov 28:218183. doi: 10.1016/j.canlet.2025.218183.
    >> Share

    October 2025
  7. NIKHIL K, Kamra M, Raza A, Shah K, et al
    Corrigendum to "Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo" [Cancer Lett. 498 (2021) 1-18].
    Cancer Lett. 2025 Oct 17:218044. doi: 10.1016/j.canlet.2025.218044.
    >> Share

    September 2025
  8. AHMAD G, El Sadda R, Botchkina G, Ojima I, et al
    Corrigendum to "Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 Inhibits prostate cancer stem cell-induced tumor growth" [Cancer Lett. 2017 Aug 11;406:71-80].
    Cancer Lett. 2025 Sep 23:218043. doi: 10.1016/j.canlet.2025.218043.
    >> Share

    August 2025
  9. NIKHIL K, Chang L, Viccaro K, Jacobsen M, et al
    Corrigendum to "Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer" [Cancer Lett 448 (2019)182-196].
    Cancer Lett. 2025 Aug 25:217999. doi: 10.1016/j.canlet.2025.217999.
    >> Share

  10. GU R, Janknecht J, Oh S, Jiang H, et al
    Anti-tumor activity of CDYL2b in prostate cancer.
    Cancer Lett. 2025 Aug 12:217987. doi: 10.1016/j.canlet.2025.217987.
    >> Share

  11. THARIAN L, Verma S, Feinberg D, Parameswaran R, et al
    Chimeric Antigen Receptor-Engineered (CAR)-T Cell Therapy for Metastatic Prostate Cancer.
    Cancer Lett. 2025 Aug 12:217986. doi: 10.1016/j.canlet.2025.217986.
    >> Share

    July 2025
  12. CHENG B, Luo T, Wu Y, Hu J, et al
    Urinary Exosomal FAM153C-RPL19 Chimeric RNA as a Diagnostic and Prognostic Biomarker for Prostate Cancer in Chinese Patients.
    Cancer Lett. 2025 Jul 18:217938. doi: 10.1016/j.canlet.2025.217938.
    >> Share

  13. MOLONY RD, Akash MMH, Kerns SL, Marples B, et al
    Extracellular vesicle proteomics identify neutrophils as potential mediators of bladder radiotoxicity in prostate cancer.
    Cancer Lett. 2025;631:217931.
    >> Share

  14. SONG Y, Zhang C, Shao D, Song X, et al
    CircRHOBTB3 suppresses MAOA by promoting cytoplasmic retention of NONO to inhibit prostate cancer proliferation and metastasis.
    Cancer Lett. 2025;631:217910.
    >> Share

  15. DENG K, Pallmann N, Livgard M, Kildal W, et al
    Endoplasmic Reticulum Stress-Driven Nucleotide Catabolism Fuels Prostate Cancer.
    Cancer Lett. 2025 Jul 3:217888. doi: 10.1016/j.canlet.2025.217888.
    >> Share

    June 2025
  16. ZHANG M, Xu Z, Cao Y, Gao C, et al
    Analysis and characterization of extrachromosomal circular DNA in prostate cancer: Potential biomarker discovery from urine, plasma, and tumor samples.
    Cancer Lett. 2025;628:217875.
    >> Share

    May 2025
  17. JIANG H, Zeng Y, Ning W, Hong J, et al
    Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B beta-hydroxybutyrylation.
    Cancer Lett. 2025 May 18:217808. doi: 10.1016/j.canlet.2025.217808.
    >> Share

    April 2025
  18. CAI S, Deng Y, Zou Z, Tian W, et al
    Metformin inhibits the progression of castration resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation.
    Cancer Lett. 2025 Apr 9:217694. doi: 10.1016/j.canlet.2025.217694.
    >> Share

    February 2025
  19. CHAN HY, Wang Q, Howie A, Bucci J, et al
    Extracellular vesicle biomarkers redefine prostate cancer radiotherapy.
    Cancer Lett. 2025 Feb 18:217568. doi: 10.1016/j.canlet.2025.217568.
    >> Share

  20. SUBRAMANIAM S, Jeet V, Gunter JH, Clements JA, et al
    Lactoferrin-Encapsulated Dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer.
    Cancer Lett. 2025 Feb 7:217522. doi: 10.1016/j.canlet.2025.217522.
    >> Share

    January 2025
  21. HINDES MT, McElligott AM, Best OG, Ward MP, et al
    Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer.
    Cancer Lett. 2025 Jan 2:217441. doi: 10.1016/j.canlet.2025.217441.
    >> Share

    November 2024
  22. LIU R, Zou Z, Zhang Z, He H, et al
    Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC.
    Cancer Lett. 2024;605:217286.
    >> Share

  23. MUNIYAN S, Vengoji R, Nimmakayala RK, Seshacharyulu P, et al
    PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer.
    Cancer Lett. 2024 Nov 25:217355. doi: 10.1016/j.canlet.2024.217355.
    >> Share

  24. STEINER L, Eldh M, Offens A, Veerman RE, et al
    Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.
    Cancer Lett. 2024;609:217352.
    >> Share

    October 2024
  25. GURUVAYURAPPAN GK, Frankenbach-Desor T, Laubach M, Klein A, et al
    Clinical Challenges in Prostate Cancer Management: Metastatic Bone-tropism and The Role of Circulating Tumor Cells.
    Cancer Lett. 2024 Oct 30:217310. doi: 10.1016/j.canlet.2024.217310.
    >> Share

    August 2024
  26. HE Q, Zhang Y, Li W, Chen S, et al
    Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.
    Cancer Lett. 2024;602:217214.
    >> Share

  27. WANG X, Zhang L, Cheng L, Wang Y, et al
    Extracellular Vesicle-derived Biomarkers in Prostate Cancer Care: Opportunities and Challenges.
    Cancer Lett. 2024 Aug 12:217184. doi: 10.1016/j.canlet.2024.217184.
    >> Share

  28. LIU D, Wang L, Guo Y
    Advances in and Prospects of Immunotherapy for Prostate Cancer.
    Cancer Lett. 2024 Aug 8:217155. doi: 10.1016/j.canlet.2024.217155.
    >> Share

    June 2024
  29. LIU YN, Liu MK, Wen YC, Li CH, et al
    Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.
    Cancer Lett. 2024 Jun 28:217090. doi: 10.1016/j.canlet.2024.217090.
    >> Share

  30. CLARK A, Villarreal MR, Huang SB, Jayamohan S, et al
    Targeting S6K/NFkappaB/SQSTM1/Poltheta signaling to suppress radiation resistance in Prostate Cancer.
    Cancer Lett. 2024 Jun 24:217063. doi: 10.1016/j.canlet.2024.217063.
    >> Share

  31. LIU C, Chen J, Cong Y, Chen K, et al
    PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
    Cancer Lett. 2024 Jun 18:217068. doi: 10.1016/j.canlet.2024.217068.
    >> Share

  32. CHEN HJ, Yu MM, Huang JC, Lan FY, et al
    SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer.
    Cancer Lett. 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070.
    >> Share

    May 2024
  33. KAUSHAL JB, Takkar S, Batra SK, Siddiqui JA, et al
    Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.
    Cancer Lett. 2024;593:216954.
    >> Share

    March 2024
  34. KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
    Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Cancer Lett. 2024;588:216815.
    >> Share

  35. RODRIGO-FAUS M, Vincelle-Nieto A, Vidal N, Puente J, et al
    CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.
    Cancer Lett. 2024 Mar 1:216776. doi: 10.1016/j.canlet.2024.216776.
    >> Share

    February 2024
  36. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    >> Share

  37. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    >> Share

  38. CHEN H, Dong K, Ding J, Xia J, et al
    CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725.
    >> Share

  39. ZHAO G, Forn-Cuni G, Scheers M, Lindenbergh PP, et al
    Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer.
    Cancer Lett. 2024 Feb 7:216657. doi: 10.1016/j.canlet.2024.216657.
    >> Share

    January 2024
  40. SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al
    Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604.
    >> Share

    November 2023
  41. ALSAMRAAE M, Costanzo-Garvey D, Teply BA, Boyle S, et al
    Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TbetaRI expression.
    Cancer Lett. 2023 Nov 6:216468. doi: 10.1016/j.canlet.2023.216468.
    >> Share

    October 2023
  42. WANG C, Wang T, Li KJ, Hu LH, et al
    SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
    Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464.
    >> Share

    September 2023
  43. SLOOTBEEK PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, et al
    PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016